Showing 541 - 560 results of 7,753 for search '"database"', query time: 0.08s Refine Results
  1. 541

    Impact of Oseltamivir and Diabetes Development by Bor-Show Tzang, Chih-Chen Tzang, Pei-Hua Chuang, I-Ying Kuo, Yu-Chun Pan, Pei-Hsun Wu, Tsai-Ching Hsu

    Published 2025-01-01
    Subjects: “…Taiwan National Health Insurance Research Database…”
    Get full text
    Article
  2. 542
  3. 543

    Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database by A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy, R. LeBlanc, K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul, D. Reece

    Published 2023-12-01
    “…This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. …”
    Get full text
    Article
  4. 544

    Not Like Everybody Else. Essays in Honor of Kees Mandemakers by Jan Kok, Hilde Bras, Richard L. Zijdeman

    Published 2021-03-01
    Subjects: “…Historical databases…”
    Get full text
    Article
  5. 545
  6. 546
  7. 547

    Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies by Rohan Khera, Yuan Lu, Harlan M Krumholz, Martijn J Schuemie, Ruijun Chen, George Hripcsak, Marc A Suchard, Patrick B Ryan, Anna Ostropolets

    Published 2022-06-01
    “…Introduction Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of cardioprotective novel agents, but without such data for older drugs, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk.Methods and analysis The large-scale evidence generations across a network of databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all four major second-line anti-hyperglycaemic agents, including sodium–glucose co-transporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas. …”
    Get full text
    Article
  8. 548
  9. 549
  10. 550
  11. 551
  12. 552
  13. 553
  14. 554

    From Matched Certificates to Related Persons by Rick Mourits, Ingrid K. van Dijk, Kees Mandemakers

    Published 2020-10-01
    Subjects: “…Historical population database…”
    Get full text
    Article
  15. 555
  16. 556

    From Matched Certificates to Related Persons by Rick Mourits, Ingrid K. van Dijk, Kees Mandemakers

    Published 2020-10-01
    Subjects: “…Historical population database…”
    Get full text
    Article
  17. 557
  18. 558
  19. 559

    From Matched Certificates to Related Persons by Rick Mourits, Ingrid K. van Dijk, Kees Mandemakers

    Published 2020-10-01
    Subjects: “…Historical population database…”
    Get full text
    Article
  20. 560